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Lung cancer is the most frequent cause of cancer death in
the Western world. Low dose Spiral CT oﬀers a new
approach to lung cancer detection and early results from
screening studies are promising. United Kingdom proposals
for a randomized controlled trial of lung cancer screening
of spiral CT vs. a control arm of no screening is discussed.
Introduction
Lung cancer is now the leading cause of cancer death in
the Western world and accounts for more deaths than
the total from colon, lung and prostate cancer combined
in the United States[1]. Although mortality from the
disease has been declining over recent years, it remains
the most common cause of cancer death in men, and
in women mortality is second only to that of breast
cancer. The vast majority (>90%) of cases are caused by
cigarette smoking. Most patients present with advanced
disease for which no curative treatment is available and
only 8–14% of patients survive 5 years[2,3]. Therefore,
novel approaches to the diagnosis and management of
lung cancer are urgently required. Non-small cell lung
cancer, which accounts for approximately 70% of all
lung cancers, may benefit from screening and early
detection because surgery for stage I disease results in
5-year survival rates ranging from 55% to over 80%[4,5].
Lung cancer screening
It is widely accepted that the only valid means of
demonstrating the eﬀect of lung cancer screening is by
means of a randomized controlled trial with mortality
from lung cancer as the primary end-point. Four ran-
domized controlled trials of lung cancer screening were
performed in the 1970s, all based on chest radiography
together with sputum cytology[6–9]. None showed evi-
dence of reduction in lung cancer mortality although
none of the trials had suﬃcient statistical power to
exclude a modest eﬀect. The results of these trials
formed the basis of the generally accepted view that lung
cancer screening is ineﬀective.
The National Cancer Institute is reassessing the role
of chest radiography in a large randomized controlled
trial, the Prostate–Lung–Colorectal–Ovarian (PLCO)
Trial, which is designed to have suﬃcient statistical
power to identify a reduction in lung cancer mortality of
10%[10]. While chest radiography may identify lung
lesions greater than 1 cm in diameter, Spiral CT can
identify pulmonary nodules less than 5 mm in diameter.
This has opened the way for the use of Spiral CT in early
detection of peripheral lung cancers.
Early results from non-randomized trials in Japan
and the United States using Spiral CT for screening lung
cancer have shown that approximately four times as
many tumours may be detected with Spiral CT than with
conventional radiography. Most of these were stage I
and are therefore likely to have a good prognosis[11–14].
The United States Early Lung Cancer Action Project
(ELCAP) trial reported by Henschke et al.[14] enrolled
1000 subjects aged 60 years or over, with at least 10 pack
years of cigarette smoking. Lung cancer was detected in
27 (2.7%) by CT and in seven (0.7%) by chest radiogra-
phy; 23 (81%) had stage I disease at diagnosis. No
cancers detected on chest radiography were missed on
Spiral CT. Annual repeat Spiral CT detected a further
seven interval cancers, all stage I[14]. Other studies from
the Mayo Clinic and Germany have shown similar
preliminary results. A recent report from Japan of a
3-year mass screening programme has demonstrated
detection of nearly 11 times the expected annual number
of early lung cancers[15].
Currently no randomized controlled trials are being
conducted for lung cancer screening using Spiral CT as
the intervention arm. The major issue regarding the
design of randomized controlled trials (RCT) of Spiral
CT is whether to use chest radiography or ‘no screening’
in the control arm. The major disadvantage of using
chest radiography as the control arm is that the results
of such an RCT would be diﬃcult to interpret as the
benefit of chest radiography, if any, is currently un-
known. Furthermore, the control arm should represent
standard practice and in most of the European studies,
including the UK, standard clinical practice is ‘no
screening’.
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While non-randomized controlled trials will provide
information on the frequency of detection of malig-
nant nodules with Spiral CT, none are designed to
examine lung cancer mortality in a screened group in
comparison with lung cancer mortality in a control
group. Therefore, they will not answer the primary
question ‘does Spiral CT screening for lung cancer
reduce lung cancer mortality?’ In the United States there
is increasing belief that Spiral CT for early lung cancer
detection is likely to be beneficial, even in the absence of
proven eﬃcacy, and demand for this service is rapidly
increasing. Thus randomized controlled trials of Spiral
CT are timely. At the present time it is impossible
to estimate the financial implications of screening
but if Spiral CT is shown to be worthwhile, it is likely
that the health impact would be as great or greater than
that of breast cancer screening. Even if screening
reduced lung cancer mortality by only 10% of all lung
cancers, it would represent more than double the
number of lives saved from breast cancer screening. The
eﬀect of Spiral CT screening may well be greater than
10%.
Spiral CT
Single-channel Spiral CT has been used in most of the
low-dose screening studies to date. However, Multi-
channel CT, now being introduced widely into clinical
practice, provides improved fast data acquisition com-
bined with excellent image quality. This new CT tech-
nology is unlikely to be superseded by a significant
alternative in the foreseeable future and is advocated for
all proposed screening trials. It is important to use the
most up-to-date technology because randomized con-
trolled trials take many years to complete and advances
in technology during the trial period may lead to
criticism of the results.
Although the risk of X-radiation exposure is
an important consideration, the dose of X-radiation
received at Spiral CT screening is likely to be less than
2.5 mSv per scan, irrespective of the type of scanner
used. Adopting the same protocol as Henschke et al.[14]
and using a scanner of above-average dose eﬃciency, the
patient dose is 1mSv[16]. This compares favourably with
the average annual environmental exposure in the UK
of 2.2 mSv, some regions receive as much as
10 mSv[16,17]. The radiation dose of Spiral CT will be
monitored in a quality control programme by the
physicist designated to the study.
The ELCAP study showed that 23% of individuals
screened with Spiral CT had pulmonary nodules but
only 2.7% of screened individuals had lung cancer,
indicating a high ratio of benign to malignant nodules.
False-positive Spiral CT examinations or false-positive
histology/cytology results from biopsy may lead to
unnecessary lung resection, introducing the risks of
morbidity and mortality associated with thoracic sur-
gery. However, in the ELCAP study no patient with a
benign nodule was referred for thoracotomy. Biopsies
were performed on 28 nodules and 27 of these were
malignant[14]. Although risks of biopsy are small, they
carry important clinical significance in elderly smokers
with chronic obstructive pulmonary disease.
Small peripheral lung cancers may be missed on the
initial Spiral CT examination although identified on a
subsequent scan. Kakinuma et al.[13] reported that seven
of 22 lung cancers were missed on initial screening
with Spiral CT but when detected at follow-up, six of
these were stage I. Lung cancers arising in the central
airways are also likely to be missed on Spiral CT as the
technique is insensitive in detecting small endo-bronchial
lesions.
The proposed UK Spiral CT Trial
In the UK in 1999 lung cancer was responsible for
34 240 deaths (22% of all cancer deaths). Proposals
for a randomized controlled trial have been developed
by the UK Cancer Coordinating Committee for
Research — Lung (UKCCCR). The primary research
objective of the UK trial is to determine whether lung
cancer screening using low-dose Spiral CT reduces mor-
tality from lung cancer. To address this issue a random-
ized controlled trial of Spiral CT vs. no screening in
smokers, 60 years and over, is proposed, with lung
cancer mortality as the primary end-point. Smoking
cessation will be oﬀered to both the screened and
unscreened group. Initially a pilot trial of 2000 individ-
uals is planned, the purpose of which is to determine the
feasibility, compliance and costs of a large randomized
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Figure 1 UK Randomized Trial Design — for 5 years. The power to detect a diﬀerence of 25% at 5% level of
statistical significance is 84%.
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It is anticipated that approximately 40 000 individuals
will be required in the full trial conducted over 5 years
to demonstrate a reduction in lung cancer mortality
of 25%. In the pilot we propose to perform Spiral
CT at baseline and then at 1 year. In the full trial
Spiral CT would be performed annually for 5 years
(Fig. 1).
The success of the pilot will be based upon the ability
to identify eligible individuals for the trial, the number
recruited, and their return for a second Spiral CT scan
after 1 year. This information will be used to determine
the size, duration and costs of the full trial, provided the
pilot is considered to be successful. In addition, the




























Figure 2 Algorithm for evaluating lung nodules.
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nodules which require further evaluation and the pro-
portion of these that are cancers including observation
of nodule growth. The algorithm for evaluating nodules
is shown in Fig. 2.
Definition and classification of nodules
A pulmonary nodule is defined as soft tissue or ground
glass opacity of rounded shape.
Category 1
Benign nodules: lesions showing central, rim, uniform or
other benign distribution of calcification; fat attenuation
within the nodule, clear linear or linear branching
densities, or known to be stable size for at least 12
months (for CT, defined as within measurement error of
up to 20%).
Category 2
Micronodules, i.e.4 mm diameter. The characteristics
and locations of all nodules will be documented for
purposes of future comparison at annual screening CT.
Category 3
Indeterminate nodules of 5–10 mm diameter whose
growth rate is, as yet, undetermined, which do not fall
into Category 1.
Category 4
Nodules >10 mm diameter which do not fall into the
description for benign nodules, or those <10 mm if
known to be enlarging on serial CT studies. Nodule
characteristics may include round or spiculated margins,
and cavitation. Focal areas of ground glass are also
included in this category.
All Category 3 nodules will be measured and observed
for tumour growth at 3, 6, 9, 12 and 24 months.
Nodule measurement
Soft tissue nodules are be measured (in mm) on standard
lung and soft tissue windows, as defined above, using the
maximum short axis (x) and long axis (y) diameters
taken at the widest point of the nodule. Tumour volume
can be calculated from the 2-dimensional measure-
ments using the prolate eclipse formula (dimension
xdimension y0.52).
Recent research using specially designed computer
software (Nodview) developed by Dr A Reeves and
colleagues[18] at the Weill Medical College of Cornell
University, New York, USA, has shown that tumours
are frequently irregular in shape and may also grow
asymmetrically. This new software, which is currently
still under development, promises to be considerably
more accurate for assessing tumour growth.
Conclusion
Lung cancer screening is being investigated throughout
the Western world using low-dose Spiral CT and some
encouraging results have already been published. A
randomized controlled trial is generally accepted as the
only method of demonstrating a reduction in disease-
specific mortality. However, as yet, no randomized trials
of lung cancer screening are being conducted. Proposals
for a UK randomized controlled trial of Spiral CT vs. no
screening are presented.
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Colorectal cancer is a major health problem worldwide.
Last year in the United States alone, more than 130 000
people were diagnosed with colorectal cancer and more
than 56 000 died of their disease[1]. Fortunately, this
neoplasm is highly suited to screening because of its long
preclinical phase, during which it is detectable and
curable[2]. Nevertheless, screening programs for colorec-
tal cancer have been only partly successful, owing
largely to poor patient compliance with screening rec-
ommendations[3,4]. A number of organizations including
the World Health Organization (WHO), the American
Cancer Society (ACS), the Agency for Health Care
Policy and Research (AHCPR), the US Preventive
Service Task Force (USPSTF), and the American
Gastroenterology Association (AGA) have issued or
endorsed guidelines for colorectal cancer screening. This
review summarizes the clinical evidence supporting
colorectal cancer screening in the average-risk popula-
tion and in high-risk groups, discusses the advantages
and disadvantages of the available screening tests, and
outlines the currently recommended guidelines for
screening based on risk category.
Average-risk population
Average-risk patients are asymptomatic individuals aged
50 years of age or older who have no personal or family
history of colorectal cancer or adenomatous polyps and
no history of inammatory bowel disease. The two most
recently published screening recommendations, those of
the ACS[5] and AHCPR[6], present guidelines for screen-
ing average-risk patients in the form of lists of options
(Table 1). The options include annual fecal occult blood
test (not included as a stand alone test in the ACS
guidelines), exible sigmoidoscopy every 5 years, annual
fecal occult blood test plus exible sigmoidoscopy every
5 years, double-contrast barium enema every 5 to 10
years, and colonoscopy every 10 years.
Fecal occult blood testing
Fecal occult blood testing (FOBT) is the safest and
least expensive of the currently available screening
tests. Three prospective, randomized, controlled trials
have demonstrated the eﬀectiveness of FOBT in
reducing colorectal cancer mortality by 15% to 33%[7–9].
However, its benefit in reducing colorectal mortality is
attributed not only to early cancer detection but also to
the incidental discovery and removal of adenomatous
polyps at subsequent colonoscopy. Such chance discov-
ery of adenomatous polyps and non-bleeding cancers by
colonoscopy has been estimated to account for 16–25%
of the colorectal cancer deaths prevented by the use of
FOBT[10]. Limitations of FOBT include its relatively
low sensitivity for detecting cancers and its inability to
detect the vast majority of adenomas[11]. Because colo-
rectal cancers bleed intermittently, 50% or more of
patients with colorectal cancer may have a negative
test result[11,12]. Thus, to be eﬀective, FOBT must be
administered annually or biennially, which makes
patient compliance a problem. Furthermore, the positive
predictive value of FOBT is only approximately
10%[11,12].
Table 1 Recommended options for colorectal cancer
screening in asymptomatic, average-risk individuals*
Starting at age 50
Annual FOBT†
Flexible sigmoidoscopy every 5 years
Annual FOBT and sigmoidoscopy every 5 years
Colonoscopy every 10 years
Double-contrast barium enema every 5–10 years
*Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer
screening: clinical guidelines and rationale. Gastroenterology 1997;
112: 594–642.
†The American Cancer Society does not recommend fecal occult
blood testing (FOBT) by itself.
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